Forbion's largest fundraising to date, with Forbion's Growth Opportunities Fund III raising €1.2 billion and Forbion Ventures Fund VII raising €890 million
Assets under management now at €5 billion
Fundraising follows strong performance, with six exits of $1 billion+ within a 12-month period
NAARDEN, The Netherlands, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Forbion, a leading global life sciences venture capital firm with deep expertise in Europe, today announces that it has raised over €2 billion ($2.2 billion) across its two newest funds, Forbion Growth Opportunities III and Forbion Ventures VII, bringing assets under management at Forbion to €5 billion ($5.5 billion). Both funds exceeded their original target sizes and reached €1.2 billion ($1.3 billion) and €890 million ($980 million) respectively.
The fundraising enables an increase of both the number of investments and the average size of Forbion's participation in future portfolio company financings, reflecting the opportunities it sees for superior returns in development-stage life sciences companies. It is anticipated that the Forbion Growth Opportunities Fund III and Forbion Ventures Fund VII will each invest in approximately 15 portfolio companies.
Sander Slootweg, Managing Partner and co-founder of Forbion, said: "I thank all our investors for their continued confidence in our ability to source and support innovative biotechs and to deliver impactful returns. With greater levels of capital, we are able to extend more support to our portfolio companies as they grow and seek to maximize their potential. We continue to see great opportunities to deploy capital in Europe and North America, backing talented management teams that develop novel therapeutics with the potential to impact the future of medicine."
Robbert van de Griendt, General Partner, Investor Relations and Impact, said: "We are delighted to have achieved this record fundraising against a backdrop of volatile market conditions. The strong demand we have seen from both existing and new investors is directly related to our strong and consistent historical returns as well as an impressive string of recent exits and also reflects investors' conviction in our specialist ...
